What We Do

Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the costs to manage these diseases will rise ten-fold within a generation.

Meeting this challenge requires pioneering approaches to accelerating treatments. The Weston Brain Institute (the “Institute”) was established to accelerate the development of therapeutics for neurodegenerative diseases of aging, using a fast, flexible and interactive funding process to provide support to researchers.

To achieve this, the Institute addresses gaps and inefficiencies in scientific research by supporting high-risk, high-reward projects while leveraging world-class business and scientific expertise. It also drives innovation in funding processes.

The Weston Brain Institute commits more than $11m each year to medical research through various programs in Canada, the Netherlands, the UK and Ireland.

The Institute is guided by its Scientific Advisory Committee and has ongoing collaborations with several organizations including the Alzheimer’s Association, Alzheimer’s Research UK, Brain Canada, and the Michael J. Fox Foundation.

The Institute was founded by The W. Garfield Weston Foundation, and continues the Foundation’s long history of support for medical research.  This support has ranged from a $1m gift to the Banting and Best Institute in the 1960s, to establishing the first Canadian Chair of Nutrition at McGill University in the 1980s, to more recently establishing The Dalglish Family 22q Clinic (formerly the Dalglish Family Hearts and Mind Clinic) at University Health Network.

Funding for the Institute’s Canadian programs comes from The W. Garfield Weston Foundation.

Funding for the Institute’s worldwide and European programs comes from the Selfridges Group Foundation.